Pilot Study Evaluating Safety of ExOlin® in Patients With Poorly Controlled Type 1 Diabetes

Launched by DEFYMED · Jan 21, 2022

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment called ExOlin® for adults with poorly controlled Type 1 Diabetes (T1D). The goal is to see if ExOlin® is safe for patients who have high blood sugar fluctuations and are prone to severe low blood sugar episodes, which can be very dangerous. To be eligible for the trial, participants must be at least 18 years old, have been diagnosed with Type 1 Diabetes for over two years, and use specific insulin therapy and continuous glucose monitoring devices. They should also have a history of severe low blood sugar or other related complications from their diabetes management.

Participants in the trial will be closely monitored while they receive ExOlin®. They can expect regular check-ups to assess their safety and how well they respond to the treatment. It's important to know that certain medical conditions may exclude someone from participating, such as severe kidney issues or active infections. This study aims to improve diabetes management and help those struggling with severe fluctuations in their blood sugar levels.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Adult men or women (age ≥ 18 years);
• • 2. Diagnosis of Type 1 Diabetes (T1D) for more than 2 years at the start of screening;
• • 3. Body mass index (BMI) \> 16 kg/m2 and \< 35 kg/m2;
• 4. Well managed intensive SubCutaneous (SC) insulin therapy, i.e. patient using for at least 3 months:
• • CSII, whatever the insulin pump used, and
• • Continuous Glucose Monitoring (CGM), by using Dexcom G6;
• • 5. 7.0% \< Serum HbA1c \< 12.0%;
• 6. Patient characterized by one of the following conditions:
• * Unstable diabetes/poor glycemic control, meaning patient presenting:
• • at least one episode of severe hypoglycemia during the 12 months prior to study screening. Severe hypoglycemia is defined by American Diabetes Association (ADA) standards as "severe cognitive impairment requiring assistance from another person for recovery" (as per ADA's definition in "standards of care in diabetes");
• • or glycemic excursions (post-prandial hyperglycemic or nocturnal hypoglycemic episodes) considered as too frequent and of high amplitude by the investigator, during the previous month;
• * Presence of adverse side effects of SC insulin-therapy:
• • SC insulin resistance;
• • or severe acquired lipodystrophy resistant to pump treatment;
• • or genetic skin atrophy or lipodystrophy.
• Exclusion Criteria:
• • 1. Renal glomerular filtration rate \<30 mL/min/1.73m2 as per Chronic Kidney Disease - Epidemiology Collaboration (CDK-EPI) calculation;
• • 2. Immunocompromised patient;
• • 3. Local or systemic acute or chronic inflammation (rheumatoid arthritis, sclerodermia);
• • 4. Active infection or inflammation;
• • 5. Known history of skin affliction that could impact ExOlin® tolerance;
• • 6. Ongoing active anticoagulant therapy;
• • 7. Severe wound healing issues;
• • 8. Parietal reinforcement prostheses;
• • 9. Known allergy to one of the devices' components, including known allergy to fixation systems (e.g. patch, plaster) for SC administration devices such as external pumps and CGM, or chronic allergy related to prolonged wearing of such systems;
• • 10. Known allergy to insulin NovoRapid®;
• • 11. Known allergy to anesthetics, or products containing iodine and its derivates, or antibiotics used during surgery (cefazolin, and combination of clindamycin and gentamycin);
• • 12. Activity contraindicated as per external pump and CGM use recommendations;
• • 13. Patient willing to practice activities with risks of trauma or major change in the environment pressure such as combat sport or scuba diving;
• • 14. Cardiac condition incompatible with surgery requirements as per anesthesiologist's opinion;
• • 15. Unstable diabetic retinopathy (as per ophthalmologist's review within 6 months before screening);
• • 16. Current or history of unresolved malignancy within 5 years before screening (with exceptions for squamous and basal cell carcinomas of the skin and carcinoma in situ of the cervix, or breast carcinoma without lymph node metastases, well-differentiated thyroid carcinoma or other non-invasive lesion that, in the opinion of the investigator, is considered as cured with minimal risk of recurrence within 5 years);
• • 17. Other surgical or medical condition that, in the judgment of the investigator, might warrant exclusion or be contraindicated, like for instance visual or hand-use symptoms;
• • 18. Mental handicap or psychiatric condition incompatible with appropriate handling of devices or compliance to treatment or investigation-related tasks;
• • 19. Known active alcohol or drug abuse;
• • 20. Having received corticoid treatment within 4 weeks prior to enrollment;
• • 21. Having received an investigational product within 12 weeks prior to enrollment, or currently participating in another clinical trial, with the exception of observational / non-interventional; registries, for which written prior approval of Defymed is needed;
• • 22. Women planning for pregnancy, being pregnant or breastfeeding or unwilling to use adequate contraceptive methods for the duration of the study (oral hormonal contraceptives, implants, injectables, hormonal or copper intrauterine device, or vasectomized partner);
• • 23. Person under guardianship, trusteeship or deprived of liberty;
• • 24. Person not affiliated to one of the French social security systems;
• • 25. Unwilling to give written informed consent to participation in the study, or unable to do so for psychiatric, cognitive or linguistic reasons.